Search

Supplementary Table S9. The predicted miRNAs that bind with FAM225A according to DIANA Tools

Supplemental Table S1. qRT-PCR primers used in this study Supplemental Table S2. siRNA sequence used in this study Supplemental Table S3. Primers used for shRNA plasmid construction Supplemental Table S4. Primers used for truncation variants plasmid construction Supplemental Table S5. Primers sequence used for ChIP-PCR assay Supplemental Table S6. Probe sequence of TINCR in situ hybridization (ISH) Supplemental Table S7. Clinical characteristics of nasopharyngeal carcinoma patients according to the high and low expression of TINCR Supplemental Table S8. Univariate and multivariable Cox regression analysis of TINCR expression level and survival Supplemental Table S9. The top10 proteins found by mass spectrometry analysis in the antisense-TINCR group (negative control). Supplemental Table S10. The top10 proteins found by mass spectrometry analysis in the TINCR group. The bold portion shows the proteins that overlap antisense-TINCR

Supplementary Table S6. The most differentially expressed lncRNAs between 3 pairs of NPC and normal nasopharynx tissues (fold change {greater than or equal to} 3, P-value < 0.05 and raw signal intensity > 1,500)

Frontier evidence suggests that dysregulation of long noncoding RNAs (lncRNA) is ubiquitous in all human tumors, indicating that lncRNAs might have essential roles in tumorigenesis. Therefore, an in-depth study of the roles of lncRNA in nasopharyngeal carcinoma (NPC) carcinogenesis might be helpful to provide novel therapeutic targets. Here we report that lncRNA TINCR was significantly upregulated in NPC and was associated positively with poor survival. Silencing TINCR inhibited NPC progression and cisplatin resistance. Mechanistically, TINCR bound ACLY and protected it from ubiquitin degradation to maintain total cellular acetyl-CoA levels. Accumulation of cellular acetyl-CoA promoted de novo lipid biosynthesis and histone H3K27 acetylation, which ultimately regulated the peptidyl arginine deiminase 1 (PADI1)–MAPK–MMP2/9 pathway. In addition, insulin-like growth factor 2 mRNA-binding protein 3 interacted with TINCR and slowed its decay, which partially accounted for TINCR upregulation in NPC. These findings demonstrate that TINCR acts as a crucial driver of NPC progression and chemoresistance and highlights the newly identified TINCR–ACLY–PADI1–MAPK–MMP2/9 axis as a potential therapeutic target in NPC.Significance:TINCR-mediated regulation of a PADI1–MAPK–MMP2/9 signaling pathway plays a critical role in NPC progression and chemoresistance, marking TINCR as a viable therapeutic target in this disease.

Long noncoding RNAs (lncRNA) play important roles in the tumorigenesis and progression of cancers. However, the clinical significance of lncRNAs and their regulatory mechanisms in nasopharyngeal carcinogenesis (NPC) are largely unknown. Here, based on a microarray analysis, we identified 384 dysregulated lncRNAs, of which, FAM225A was one of the most upregulated lncRNAs in NPC. FAM225A significantly associated with poor survival in NPC. N(6)-Methyladenosine (m6A) was highly enriched within FAM225A and enhanced its RNA stability. FAM225A functioned as an oncogenic lncRNA that promoted NPC cell proliferation, migration, invasion, tumor growth, and metastasis. Mechanistically, FAM225A functioned as a competing endogenous RNA (ceRNA) for sponging miR-590-3p and miR-1275, leading to the upregulation of their target integrin β3 (ITGB3), and the activation of FAK/PI3K/Akt signaling to promote NPC cell proliferation and invasion. In summary, our study reveals a potential ceRNA regulatory pathway in which FAM225A modulates ITGB3 expression by binding to miR-590-3p and miR-1275, ultimately promoting tumorigenesis and metastasis in NPC.Significance:These findings demonstrate the clinical significance of the lncRNA FAM225A in nasopharyngeal carcinoma (NPC) and the regulatory mechanism involved in NPC development and progression, providing a novel prognostic indicator and promising therapeutic target.

Supplementary Table S1. qPCR primers used in this study Supplementary Table S2. The FAM225A expression level and grouping of samples based on GEO dataset (GSE12452) Supplementary Table S3. Primers used for shRNA plasmid construction Supplementary Table S4. Sequence of miRNA mimic or inhibitor used in this study Supplementary Table S5. Probe sequence of FAM225A in situ hybridization (ISH) Supplementary Table S7. Clinical characteristics of nasopharyngeal carcinoma patients according to the high and low expression of FAM225A. Supplementary Table S8. Univariate and multivariable Cox regression analysis of FAM225A expression level and survival. Supplementary Table S10. Inguinal lymph node metastasis in vivo.

Supplemental Figure S1. TINCR is upregulated in six other cancer types. Supplemental Figure S2. GSEA analyses results of TINCR silencing. Supplemental Figure S3. Overexpression of TINCR promotes NPC cell proliferation, metastasis and cisplatin resistance in vitro. Supplemental Figure S4. Overexpression of TINCR reverses the suppressive effects of TINCR knockdown on cell proliferation, cisplatin resistance and metastasis. Supplemental Figure S5. TINCR targets ACLY and impairs its ubiquitination degradation. Supplemental Figure S6. Silencing TINCR has no effects on the expressions of KAT3A and KAT3B. Supplemental Figure S7. The ACLY-binding motif CUGKR is critical for the role of TINCR in maintaining ACLY protein stability and lipid synthesis levels. Supplemental Figure S8. Acetyl-CoA is responsible for TINCR-mediated NPC progression and chemoresistance. Supplemental Figure S9. Correlation between TINCR and PADI1 expression in 16 other cancer types from the TCGA database. Supplemental Figure S10. Silencing TINCR decreases the proteolytic activities of MMP2/9, but had no effects on H3K27ac levels at MMP2/9 promoters. Supplemental Figure S11. IGFBP3 is overexpressed in NPC

Supplementary Figure S1. FAM225A is overexpressed in NPC and other tumor types. Supplementary Figure S2. Silencing METTL3 resulted in the decreased m6A level of total RNA. Supplementary Figure S3. FAM225A promotes NPC cell proliferation, migration and invasion in vitro. Supplementary Figure S4. FISH assay showed that FAM225A was mainly located in cytoplasmic. Supplementary Figure S5. FAM225A acts as a ceRNA for miR-590-3p and miR-1275. Supplementary Figure S6. The expression of FAM225A is negatively correlated with miR-590-3p and miR-1275 expression. Supplementary Figure S7. Silencing of miR-590-3p and miR-1275 endows NP69 and N2Tert cells with carcinogenicity in vitro. Supplementary Figure S8. miR-590-3p/miR-1275 are responsible for FAM225A-mediated proliferation, migration and invasion. Supplementary Figure S9. Correlation between FAM225A and ITGB3 expression in 12 other cancer types from the TCGA database. Supplementary Figure S10. FAM225A promotes NPC cell metastasis in vivo. Supplementary Figure S11. ITGB3 is responsible for FAM225A-meidated tumorigenesis and metastasis in vivo.

Frontier evidence suggests that dysregulation of long noncoding RNAs (lncRNA) is ubiquitous in all human tumors, indicating that lncRNAs might have essential roles in tumorigenesis. Therefore, an in-depth study of the roles of lncRNA in nasopharyngeal carcinoma (NPC) carcinogenesis might be helpful to provide novel therapeutic targets. Here we report that lncRNA TINCR was significantly upregulated in NPC and was associated positively with poor survival. Silencing TINCR inhibited NPC progression and cisplatin resistance. Mechanistically, TINCR bound ACLY and protected it from ubiquitin degradation to maintain total cellular acetyl-CoA levels. Accumulation of cellular acetyl-CoA promoted de novo lipid biosynthesis and histone H3K27 acetylation, which ultimately regulated the peptidyl arginine deiminase 1 (PADI1)–MAPK–MMP2/9 pathway. In addition, insulin-like growth factor 2 mRNA-binding protein 3 interacted with TINCR and slowed its decay, which partially accounted for TINCR upregulation in NPC. These findings demonstrate that TINCR acts as a crucial driver of NPC progression and chemoresistance and highlights the newly identified TINCR–ACLY–PADI1–MAPK–MMP2/9 axis as a potential therapeutic target in NPC. Significance: TINCR-mediated regulation of a PADI1–MAPK–MMP2/9 signaling pathway plays a critical role in NPC progression and chemoresistance, marking TINCR as a viable therapeutic target in this disease.